
The combination of talquetamab plus daratumumab yields improved patient outcomes in those with relapsed/refractory multiple myeloma.
Your AI-Trained Oncology Knowledge Connection!
The combination of talquetamab plus daratumumab yields improved patient outcomes in those with relapsed/refractory multiple myeloma.
“We are now able to increase the lifespan in some of these most deadly forms of thyroid cancer solely due to gene profiling and targeted medicine,” said Geoffrey David Young, MD, PhD, FACS.
Extended follow-up from the CASSIOPEIA trial illustrates the PFS and MRD benefits of daratumumab-based induction/consolidation and maintenance therapy.
Data from a real-world study further illustrates clinical benefit in patients with cholangiocarcinoma receiving pemigatinib.
The fixed-dose combination of favezelimab and pembrolizumab did not show an improvement in overall survival compared with the standard of care in patients with metastatic CRC.
The approval is based on results from the global phase 3 FRESCO-2 trial, which demonstrated improvement in OS in patients with refractory metastatic colorectal cancer.
A SEER-Medicare database analysis of patients with AML illustrates a trade-off between survival outcomes and time spent in hospitals.
Datopotamab deruxtecan previously showed statistically significant improvement in progression-free survival in patients with HR+, HER2-low, or HER2-negative breast cancer.
Data from the interim analysis of the ACCENT trial showed promising signs of efficacy with narmafotinib combination therapy in advanced pancreatic cancer.
A belantamab mafodotin combination regimen has been accepted for review in Japan, based on data from the DREAMM-7 and DREAMM-8 clinical trials.
Complete responses were observed in a small cohort of patients with DLBCL who have previously received autologous CAR T-cell therapy.
DFS was improved with 1-year trastuzumab in patients with ERBB2-positive breast cancer enrolled in the SOLD trial.
Data from CCTG HE1 also show a numerical improvement an in overall survival with added radiotherapy over best supportive care alone.
Research shows that patients with pancreatic ductal adenocarcinoma are frequently understaged prior to surgery.
The use of 5-fluorouracil decreased toxicity and possible savings in first-line advanced gastrointestinal cancers.
Recent FDA approval of the companion diagnostics may help improve personalized treatment decision-making for patients with prostate cancer.